UCI Proposed RCT on Glutathione Deficiency and MSIDS Abnormalities in COVID Longhaulers.
The Role of Glutathione Deficiency, NF-κB blockade, and MSIDS Variables in PASC: The Nutraceuticals in Longhaulers Trial (‘NIL’ trial)
July 31st, 2021, IRB submission, MINIMUM Testing
Richard I. Horowitz, MD
Medical director, Hudson Valley Healing Arts Center
Board certified internal medicine
Member NYS DOH Tick-borne Disease Working Group 2021
Member HHS Tick-borne Disease Working Group 2017-2019
Co-chair HHS Other Tick-borne Diseases and Co-infections subcommittee 2017-2019
Member, HHS Babesia and Other Tick-borne Pathogens 2019-2020
A hypothetical three-part prevention, diagnostic, and treatment approach based on an up-to-date scientific literature review for COVID-19 was published by Horowitz et al. in 2020.1 The primary hypothesis behind designing an effective prevention and treatment approach was based on the medical literature showing that infection, immune dysfunction, and inflammation (3 I’s) cause severe symptoms/clinical manifestations in COVID-19. Pathogenicity of COVID-19 has been linked in some patients to “Cytokine Storm Syndrome” (CSS) with “Acute Respiratory Distress Syndrome” (ARDS), which is the primary cause of death, along with fulminant myocarditis and multiorgan dysfunction. This results from an uncontrolled systemic inflammatory response with an increase in large amounts of pro-inflammatory cytokines (IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, TNF-α, TGFβ, etc.) & chemokines (CXCL9, CXCL10, etc.) by immune effector cells. 2 3 Recent scientific research has determined that not all patients who succumb to COVID-19 have evidence of a cytokine storm however, and the etiology underlying severe acute and chronic manifestations is still being investigated.